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TREM2 is a receptor for non-glycosylated mycolic
acids of mycobacteria that limits antimycobacterial macrophage activation
1234567890():,;

Ei’ichi Iizasa 1, Yasushi Chuma2, Takayuki Uematsu 3, Mio Kubota4, Hiroaki Kawaguchi5,
Masayuki Umemura6, Kenji Toyonaga 1,7, Hideyasu Kiyohara2, Ikuya Yano2,8, Marco Colonna 9,
Masahiko Sugita10, Goro Matsuzaki6, Sho Yamasaki 7, Hiroki Yoshida 4 & Hiromitsu Hara 1 ✉

Mycobacterial cell-wall glycolipids elicit an anti-mycobacterial immune response via FcRγassociated C-type lectin receptors, including Mincle, and caspase-recruitment domain family
member 9 (CARD9). Additionally, mycobacteria harbor immuno-evasive cell-wall lipids
associated with virulence and latency; however, a mechanism of action is unclear. Here, we
show that the DAP12-associated triggering receptor expressed on myeloid cells 2 (TREM2)
recognizes mycobacterial cell-wall mycolic acid (MA)-containing lipids and suggest a
mechanism by which mycobacteria control host immunity via TREM2. Macrophages respond
to glycosylated MA-containing lipids in a Mincle/FcRγ/CARD9-dependent manner to produce inﬂammatory cytokines and recruit inducible nitric oxide synthase (iNOS)-positive
mycobactericidal macrophages. Conversely, macrophages respond to non-glycosylated MAs
in a TREM2/DAP12-dependent but CARD9-independent manner to recruit iNOS-negative
mycobacterium-permissive macrophages. Furthermore, TREM2 deletion enhances Mincleinduced macrophage activation in vitro and inﬂammation in vivo and accelerates the elimination of mycobacterial infection, suggesting that TREM2-DAP12 signaling counteracts
Mincle-FcRγ-CARD9-mediated anti-mycobacterial immunity. Mycobacteria, therefore, harness TREM2 for immune evasion.
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uberculosis (TB) is a chronic infectious disease caused by
Mycobacterium tuberculosis (Mtb), and remains a major
cause of morbidity and mortality worldwide. Most infected
individuals do not manifest clinical symptoms of TB (referred to
as latent infection). In this phase, the bacteria are dormant with a
nonreplicating phenotype and resistant to reactive intermediates
and antibiotics, consistently evading host immune recognition1.
A distinctive trait of mycobacteria is their highly lipid-rich
outer membrane, which is not only critical for their replication,
acid-fast properties, and drug resistance, but also plays a key role
in pathogenicity2,3 Some of these lipids trigger immunopathologic response, whereas others have immuno-evasive functions
associated with virulence and latency4. Mycolic acids (MAs) are
mycobacterium and related spp.-speciﬁc lipids with extremely
long fatty acids (C60–C90) and represent predominant component
in mycobacterial cell walls. MAs form the cell wall skeleton by
covalently linking to the arabinogalactan (ABG) and peptidoglycan (PGN) basement layer, and also exist on the cell wall
surface in either glycosylated or non-glycosylated forms5. Their
composition is altered dynamically depending on mycobacterial
life cycle stage and external environmental conditions6,7, and this
affects bacterial virulence and latency by controlling host
immunity. For example, glycosylated MA-containing lipids, such
as trehalose dimycolate (TDM; also known as cord factor) and
glucose monomycolate (GMM), possess potent pro-inﬂammatory
and adjuvant activity and are capable of inducing lung granulomas when injected into animals8,9. These glycolipids are predominantly synthesized in actively replicating mycobacteria,
while their levels are markedly diminished in dormant
mycobacteria6. Non-glycosylated MA lipids, such as free MA
(fMA) and glycerol monomycolate (GroMM), are associated with
mycobacterial persistence, immune suppression, and bioﬁlm
formation. fMA is increased in cell walls in nonreplicating persistent mycobacteria6, forms bioﬁlms10,11, and also inhibits
cytokine production and phagosome–lysosome fusion in macrophages. A hypervirulent mutant Mtb strain (Δmce1) with a disruptied mce1 operon, which results in excess accumulation of
fMA in the cell wall12,13, induces a weak macrophage chemokine
response14, fails to elicit a strong Th1 response, and causes poorly
organized lung granulomas in mice13, relative to that of the wildtype (WT) strain. GroMM is associated with latent infection15,
and induces eosinophilic inﬂammation and T helper (Th)2-type
cytokine production16, which might counteract Th1-mediated
antimycobacterial immunity. However, the molecular mechanisms by which these non-glycosylated MA lipids modulate host
immunity remain unclear.
Although pathogen recognition by macrophages usually triggers the immune responses that eliminate the pathogens, macrophages are the primary target cells of Mtb and serve as an
intracellular niche for Mtb propagation and latency17. Mtb has
evolved remarkable immune evasion strategies that enable
intracellular persistence in macrophages18. The cell wall lipids
phthiocerol dimycocerosates (PDIMs) and the structurally related
phenolic glycolipids (PGLs) represent virulence factors found
only in a limited subset of pathogenic mycobacteria, such as
hypervirulent W-Beijing strains of Mtb19. The surface expression
of these lipids on mycobacteria masks ligands for toll-like
receptors (TLRs) that are required for the induction of inducible
nitric oxide synthase (iNOS)-positive M1-type microbicidal
macrophages, and instead recruits iNOS-negative non-microbicidal macrophages (referred to as “permissive macrophages”) to
the site of infection, thereby facilitating the intracellular Mtb
survival and propagation20. The recruitment of permissive macrophages is dependent on CCR2 and the induction of its ligand
monocyte chemoattractant protein-1 [MCP-1 (CCL2)] by PGL
through activation of the STING cytosolic sensing pathway20,21.
2

Evidence for the importance of immunoreceptor tyrosinebased activation motif (ITAM)-coupled receptors, including Ctype lectin receptors (CLRs) and immunoglobulin superfamily
receptors, is accumulating with regard to innate immunity against
a variety of pathogens22–25. These receptors associate with the
ITAM-bearing signaling adaptors DAP12 or FcRγ, or harbor
cytoplasmic ITAM-like motifs called hemITAM for signal
transduction26. Ligand recognition by these receptors triggers
tyrosine phosphorylation in ITAM, followed by activation of the
tyrosine kinase Syk, leading to the downstream activation of
mitogen-activated protein kinases and nuclear factor-kappa B
through the signaling adaptor caspase recruitment domain family
member 9 (CARD9). CARD9 acts in complex with B-cell lymphoma/leukemia-10 and mucosa-associated lymphoid tissue
lymphoma translocation protein-1, and plays an essential role in
ITAM-coupled receptor-induced myeloid cell activation26,27.
Recent reports highlight the importance of CARD9 and the FcRγassociated CLRs, which recognize mycobacterial cell wall glycolipids, in antimycobacterial innate immunity28. CARD9-deﬁcient
mice are highly susceptible to Mtb infection29. Mincle (Clec4e)
recognizes TDM to elicit pulmonary inﬂammation and induces
granuloma formation in an FcRγ-dependent manner30. MCL
(Dectin-3/Clec4d) also recognizes TDM and form a dimer with
Mincle to stabilize its surface expression31,32. Dectin-2 (Clecsf10)
recognizes mannose-capped lipoarabinomannan (LAM), and
plays a central role in production of IL-10 and IL-2 during
mycobacterial infection33. DCAR (mouse Clec4b1) recognizes
phosphatidylinositol mannosides, and promotes monocyte
recruitments and the Th1 responses34. In contrast to CLRassociated FcRγ, the other ITAM-bearing signaling adaptor,
DAP12, might negatively regulate the antimycobacterial immune
response, because DAP12 deﬁciency accelerates the clearance of
mycobacteria and the granuloma formation in lungs upon Mtb or
Mycobacterium bovis Bacille de Calmette et Guerin (BCG)
infection35,36. These observations implicate unknown DAP12associated regulatory receptors that might possibly recognize
immune-suppressive ligands in mycobacteria. However, these
theoretical receptors, as well as the precise mechanisms of
immune suppression via DAP12, have not been described.
In the present study, we present evidence suggesting that the
DAP12-associated receptor triggering receptor expressed on
macrophage 2 (TREM2) recognizes mycobacterial MAcontaining lipids that are distinct from those recognized by
Mincle and counteracts the Mincle–FcRγ–CARD9-mediated
antimycobacterial immune response. We show that the glycosylated MA-containing lipids induce mycobactericidal macrophages
in a Mincle/FcRγ/CARD9-dependent manner. Conversely, the
non-glycosylated MA-containing lipids induce mycobacteriapermissive macrophages in a TREM2/DAP12-dependent but
CARD9-independent manner. Moreover, loss of TREM2 markedly enhances Mincle-induced macrophage activation in vitro
and inﬂammation in vivo, and accelerated the elimination of
mycobacterial infection in mice. These results suggest that
mycobacteria evade host immunity via TREM2 to avoid mycobactericidal macrophage activation through the Mincle–CARD9
pathway. This ﬁnding describes a mechanism by which mycobacteria controls the host immune response through a host regulatory innate immune receptor, which may have implications for
treatment of mycobacteriosis, including TB.
Results
TREM2 recognizes mycobacteria. To screen novel ITAMcoupled receptors capable of recognizing mycobacteria, we analyzed the binding of 20 known ITAM-coupled CLR, TREM,
and leukocyte mono-Ig-like receptor (LMIR; CD300) family
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Fig. 1 TREM2 recognizes mantihumanycobacteria. a Heat-killed Mtb H37Ra or H37Rv, or M. bovis BCG were incubated with the indicated CLR, TREM, and
LMIR family receptors fused to the Fc-antibody fragment or with the control Fc fragment, followed by staining with antihuman IgG-FITC secondary
antibody. The binding of each receptor-Fc protein was analyzed by ﬂow cytometry. Open histograms show binding data for the indicated receptor-Fc
proteins. The gray-ﬁlled histograms show background ﬂuorescence of the control staining. b NFAT-GFP reporter cells expressing TREM2 + DAP12 or
DAP12 alone were stimulated with the indicated amounts of heat-killed Mtb H37Ra or H37Rv, or M. bovis BCG for 24 h, followed by analysis of GFP
ﬂuorescence by ﬂow cytometry. The histograms on the left indicate the data from stimulation with 100 μg/ml of the indicated mycobacteria. Data in the
right panels are presented as percent increase over control values of unstimulated cells. Data are presented as the mean ± SEM of duplicate assays and
representative of three independent experiments. Source data are provided as a Source data ﬁle.

receptors22,37–39 fused to Fc-antibody fragments to heat-killed
mycobacterial strains, including the virulent strain Mtb H37Rv,
the attenuated strain Mtb H37Ra, and the vaccine strain M. bovis
BCG, using ﬂow cytometry. In addition to several CLRs previously reported to recognize mycobacteria, including Mincle,
speciﬁc ICAM-3 grabbing nonintegrin-related (SIGNR)1,
SINGNR3, and DC-SIGN30,40, this screening identiﬁed TREM2
and LMIR5 as novel receptors capable of binding to mycobacteria
(Fig. 1a). Especially, TREM2 demonstrated a strong binding
capacity to all tested mycobacterial strains, which prompted us to
further characterize this interaction.
To investigate whether recognition of mycobacteria by TREM2
activates intracellular ITAM signaling, we used nuclear factor of
activated T cells (NFAT)-driven green ﬂuorescent protein (GFP)
reporter cells (2B4)30 ectopically expressing TREM2 and its
signaling subunit DAP12 (refs. 41,42). As reported previously30,
Mtb H37Rv, Mtb H37Ra, and M. bovis BCG stimulated NFATGFP signaling in reporter cells expressing Mincle and FcRγ
(Supplementary Fig. 1a). We found that all these mycobacterial
strains clearly activated reporter cells expressing TREM2 and
DAP12, but not in those expressing only DAP12, in a dosedependent manner (Fig. 1b). Whereas, none of these strains
activate reporter cells expressing TREM1 plus DAP12 (Supplementary Fig. 1b). Importantly, the level of stimulation by TREM2

and Mincle differed between the strains (Fig. 1b and Supplementary
Fig. 1a), suggesting that TREM2 and Mincle recognize different
ligands commonly expressed by these mycobacterial strains.
TREM2 recognizes MAs. TREM2 binding to mycobacteria
implies that its ligand(s) exist on the cell wall surface, where
mycobacteria express a wealth of unique lipids that inﬂuence the
host immune responses43. Given that TREM2 binds to various
endogenous mammalian lipids44,45, we ﬁrst examined whether
mycobacterial lipids contain TREM2 ligand(s). De-lipidation of
Mtb H37Ra with chloroform and methanol (C:M; Fig. 2a)
markedly diminished the level of stimulation in TREM2 reporter
cells (Fig. 2b), as well as in Mincle reporter cells as reported30
(Fig. 2c). Accordingly, the lipid-containing C:M fraction (Fig. 2a),
but not the hydrophilic M:W fraction showed strong stimulating
activity in TREM2 reporter cells (Fig. 2b) as with Mincle reporter
cells (Fig. 2c), implicating that TREM2 ligands were present in
the cell wall lipid fraction as with so Mincle ligands30. We then
next tested the TREM2-stimulating activity using known major
constituents of mycobacterial cell wall, including the glycans PGN
and ABG, the immunostimulatory glycolipids LAM and TDM
(Fig. 2d), and fMA (Fig. 2d). We observed that ABG, PGN, and
LAM did not activate the TREM2 reporter cells, even at higher
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Fig. 2 TREM2 recognizes MAs. a Schematic diagram of solvent-based de-lipidation and fractionation of Mtb H37Ra. Bacteria were de-lipidated by the
treatment with chloroform/methanol. After centrifugation (cfg.), soluble extracts (sup) were mixed with water and separated into the lipid-soluble (C:M)
and the water-soluble methanol:water (M:W) fractions. b, c NFAT-GFP reporter cells expressing TREM2 + DAP12 (b) or Mincle + FcRγ (c) were
stimulated for 24 h with either untreated or de-lipidated bacteria (ppt) or plate-coated C:M or M:W fractions indicated in a, followed by analysis of GFP
ﬂuorescence by ﬂow cytometry. d Chemical structure of TDM. The structure of α-mycolate-containing TDM is shown. e–g NFAT-GFP reporter cells
expressing TREM2 + DAP12 or DAP12 alone were stimulated with the indicated amounts of ABG (e), PGN (f), and LAM (g) for 24 h, followed by analysis
of GFP ﬂuorescence by ﬂow cytometry. Data are presented as percent increase over control values of unstimulated cells. h, i NFAT-GFP reporter cells
expressing TREM2 + DAP12 or DAP12 only (h) or Mincle + FcRγ (i) were stimulated with the indicated amounts of TDM or fMA, and analyzed as
described in e–g. j, k NFAT-GFP reporter cells expressing TREM2 + DAP12 were stimulated with the indicated amounts of BCG MA, R. equi MA, or BA (j)
or THA, PA, or HBA (k) and analyzed as described in e–g. Data are presented as the mean ± SEM of duplicate (b, c, e–i, j) or triplicate (k) assays and
representative of three independent experiments. Source data are provided as a Source data ﬁle.

concentrations (Fig. 2e–g), whereas we observed substantial
ligand activity with TDM and fMA (Fig. 2h). Importantly, loss of
trehalose moiety from TDM (i.e., fMA) markedly increased the
TREM2-stimulating activity (Fig. 2h), while it completely abolished the Mincle-stimulating activity as reported (Fig. 2i)30. These
results suggest that TREM2 recognizes the MA moiety of TDM,
and that the sugar moiety interferes with this recognition.
4

We then investigated the structure of MA necessary for TREM2
recognition. Extremely long (C60–C90) and branched alkyl chains
are hallmarks of mycobacterial MAs. To assess the importance of
the length and branching, we compared the stimulatory activity of
mycobacterial MA with that of Rhodococcus equi MA, which has
shorter alkyl chains (C35), and of behenic acid (BA), which is a
linear fatty acid with an alkyl chain (C22) of similar length with the
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Fig. 3 TREM2 and Mincle preferentially recognize distinct MA-containing lipids based on their glycosylation. a Chemical structure of glycosylated
(TDM and GMM) and non-glycosylated (GroMM and fMA) MA-containing lipids found in Mtb. The structures of α-mycolate-containing lipids are
included. b The indicated amounts of TREM2 or Mincle-Fc fusion proteins were added to wells coated with 0.5 μg/well TDM, GMM, GroMM, or fMA,
followed by incubation with anti-human IgG-horseradish peroxidase and detection of bound proteins using an enzyme-linked immunosorbent assay
(ELISA)-based colorimetric assay. c NFAT-GFP reporter cells expressing TREM2 + DAP12 or Mincle + FcRγ were stimulated with the indicated amounts of
TDM, GMM, GroMM, or fMA coated on the plates for 24 h, followed by analysis of GFP ﬂuorescence by ﬂow cytometry. Values are plotted as percent
maximal response of the largest value. Data are presented as mean ± SEM of duplicate assays and are representative of at least three independent
experiments. Source data are provided as a Source data ﬁle.

mero-chain of R. equi MA (Fig. 2j). R. equi MA exhibited a similar
level of stimulatory activity in TREM2 reporter cells as
mycobacterial MA, whereas the level of stimulation with BA was
very low, even at higher concentrations of BA (Fig. 2j), suggesting
that the branched structure rather than the alkyl chain length was
important for TREM2 recognition of MA. To further investigate
this, we tested the ligand activity of palmitic acid (PA; C16), 2tetradecylhexadecanoic acid (THA; C14/C16), which bears a PAbased synthetic fatty acid with similar branching structure as MA,
but lacking its 3-hydroxyl residue, and 3-hydroxybutyric acid
(HBA), which has only the carboxyl and hydroxyl residue at the
branching moiety of MA (Fig. 2k). We detected TREM2 stimulation with THA, albeit at a lower level than MA, but could not
detect stimulation with PA and HBA (Fig. 2k), suggesting that
TREM2 recognition requires a branched fatty acid structure with
an alkyl chain.
The R47H mutation in TREM2, which is associated with a
higher risk of several neurodegenerative diseases46–49, impairs the
recognition of brain lipids45,50. We found that the TREM2 R47H
mutation also attenuated MA recognition (Supplementary Fig. 2),
suggesting that this residue is important for MA recognition
by TREM2.
Contrasting recognition of MA-containing lipids by Mincle
and TREM2. Mycobacteria express a variety of MA-containing
lipids on their cell wall51. Since both Mincle and TREM2 have the
capacity to recognize MA-containing lipids, we next compared
their binding activity to the glycosylated (TDM and GMM) or the

non-glycosylated (GroMM and fMA) MA-containing lipids
(Fig. 3a). using the receptor-Fc fusion proteins. We observed that
Mincle-Fc not only showed strong binding to TDM as expected,
but also binding to GMM, whereas it showed no detectable
binding to fMA and weak binding to GroMM only at higher
concentrations (Fig. 3b). By contrast, TREM2-Fc showed strong
binding to GroMM and fMA, but showed relatively much weaker
binding to TDM and GMM (Fig. 3b). We then examined whether
the different binding of MA-containing lipids to TREM2 and
Mincle reﬂect their receptor-stimulatory activities using NFATGFP reporter cells. Consistent with the binding data, TREM2
reporter cells strongly responded to MA and GroMM, but weakly
to TDM and GMM, whereas Mincle reporter cells responded
strongly to TDM and GMM, but weakly to GroMM only at
higher concentrations and did not respond to fMA (Fig. 3c).
Therefore, TREM2 and Mincle preferentially recognize nonglycosylated and glycosylated MA-containing lipids, respectively.
Mincle and TREM2 induce distinct macrophage activation. To
investigate the relevance of TREM2 and Mincle recognition of
MA-containing lipids in the activation of innate immune cells, we
stimulated peritoneal macrophages from WT, TREM2-deﬁcient
(Trem2−/−), or Mincle-deﬁcient (Clec4e−/−) mice with either
glycosylated or non-glycosylated MA-containing lipids and
examined their production of MCP-1, a pivotal monocyte chemoattractant implicated in TB pathology52–54, and TNF, an
essential cytokine for granuloma formation and TB control55,56.
Interestingly, we found that the activation of WT macrophages by
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the glycosylated MA-containing lipids TDM or GMM or by
lipopolysaccharide (LPS) induced production of both MCP-1 and
TNF, whereas activation of macrophages with the nonglycosylated MA-containing lipids GroMM or fMA induced
production of MCP-1 but not TNF (Fig. 4a), as well as other proinﬂammatory cytokines, including IL-6 and IL-12p40 (Supplementary Fig. 3a). Loss of Mincle almost completely abolished
TNF, as previously30, as well as MCP-1 in response to TDM as
expectedly30. We found that Mincle deﬁciency also abolished
these productions induced by GMM (Fig. 4a). However, Mincle
deﬁciency did not affect MCP-1 production in response to
GroMM or fMA. By contrast, loss of TREM2 almost completely
abolished the MCP-1 production in response to GroMM or MA,
but not to TDM or GMM (Fig. 4a). These results demonstrated
that glycosylated and non-glycosylated MA-containing lipids
elicited distinct macrophage activation, which was dependent on
Mincle and TREM2, respectively.
Triggering of ITAM-coupled receptors on myeloid cells
activates the ITAM–Syk–CARD9 signaling pathway to induce
cytokine production57. To investigate whether MCP-1 and TNF
production induced by MA-containing lipids depends on this
pathway, we ﬁrst conﬁrmed the requirement for DAP12 and
FcRγ, which are the ITAM-containing signaling subunits of
TREM2 and Mincle, respectively. As expected, we observed that
FcRγ-deﬁcient (Fcer1g−/−) and DAP12-deﬁcinet (Tyrobp−/−)
macrophages almost phenocopied Mincle-deﬁcient and TREM2deﬁcient macrophages, respectively, with similar patterns of
defects in TNF and MCP-1 productions in response to
glycosylated or non-glycosylated MA-containing lipids (Fig. 4b).
However, FcRγ deﬁciency slightly dampened MCP-1 induction
by fMA or GroMM at higher concentrations, implicating that
FcRγ might partly contribute to TREM2 signaling. We then
examined the requirement for Syk and CARD9 for each of these
responses. Treatment of WT macrophages with a Syk inhibitor
(BAY-613606) abrogated both MCP-1 and TNF production in
response to all MA-containing lipids (Fig. 4c), indicating essential
role for Syk in the response to these lipids. Intriguingly, although
TNF production induced by glycosylated MAs through Mincle
was abolished in CARD9-deﬁcient (Card9−/−) macrophages, as
expected58, CARD9-deﬁciency did not affect MCP-1 production
induced by both glycosylated and non-glycosylated MA-containing lipids (Fig. 4c). Collectively, these results demonstrated that
mycobacterial MA-containing lipids induced TNF production
through Mincle via the canonical FcRγ–Syk–CARD9 pathway,
while they induced MCP-1 production via the ITAM–Syk
pathway, but independent of CARD9 signaling (Supplementary
Fig. 3b).
TREM2/DAP12 signal inhibits Mincle-induced macrophage
activation. Interestingly, we observed that loss of TREM2
markedly enhanced MCP-1 and TNF production by peritoneal
macrophages in response to TDM or GMM (Fig. 4a). This was
also true in Tyrobp−/− macrophages (Fig. 4b), suggesting an
inhibitory role of TREM2/DAP12 signaling in Mincle/FcRγinduced macrophage activation. We did not observe an increase
in cytokine response when the same preparation of Trem2−/−
macrophages were stimulated with TLR ligands, such as
Pam3CSK4 (for TLR2), LPS (for TLR4), Poly (I:C) (for TLR3),
CpG-ODN (for TLR9), or with the Dectin-1 ligand zymozan
(Fig. 4a and supplementary Fig. 4a, b). This selective enhancement of Mincle activation in the absence of TREM2 was more
prominent in bone marrow-derived macrophages (BMDMs),
where TDM-induced TNF was detected at very low levels in WT
BMDMs. Nevertheless, Trem2−/− or Tyrobp−/− BMDMs showed
substantial TNF production in response to TDM (Supplementary
6

Fig. 4c), whereas this enhancement was not observed following
Pam3CSK4 or LPS stimulation. In addition, we observed an
increased cytokine response following stimulation of Trem2−/−
BMDMs with mycobacterial total lipids (C:M fraction in Fig. 2a)
prepared from Mtb R37Ra or M. bovis BCG (Supplementary
Fig. 4d). This response was largely dependent on Mincle, as
Clec4e−/− BMDMs produced markedly lower TNF in response to
the total lipids compared to WT BMDMs (Supplementary
Fig. 4d). These data clearly indicated that TREM2/DAP12signaling selectively inhibited macrophage activation induced by
Mincle–FcRγ signaling.
Triggering of TREM2 induces permissive macrophages. Given
that NO plays a pivotal role in controlling mycobacterial
infections59,60, we investigated the action of TREM2 and Mincle
on NO production by macrophages. We observed that TDM
stimulation strongly induced NO production by BMDMs, as
reported previously30, while fMA did not substantially induce NO
production (Fig. 5a). This was consistent with the observed
increase in Nos2 expression, which encodes iNOS, after stimulation with TDM but not fMA (Supplementary Fig. 5a). In
addition, the TDM-induced NO production by macrophages was
inhibited following the addition of a TNF-blocking antibody
(Fig. 5b). Inversely, addition of recombinant TNF to the fMAstimulated culture induced NO production by macrophages
(Fig. 5b), indicating that NO production was dependent on TNF,
which is consistent with previous ﬁndings61–63.
We then characterize the inﬂammation triggered via Mincle
and TREM2 in vivo. Because TDM induces lung granulomas in
mice via the Mincle/FcRγ pathway30, we examined whether fMA
had a similar effect. Intravenous injection of a TDM (oil-in-water)
emulsion into mice induced massive granulomatous lesions in the
lungs, which was completely abolished in Clec4e−/− mice (Fig. 5c),
as reported previously30. In addition, this effect was also absent in
Card9−/− mice, indicating that TDM-induced granuloma formation was dependent on Mincle/CARD9 signaling. By contrast, we
did not observe lung granulomatous lesions in mice injected with
an fMA emulsion (Fig. 5c), suggesting that fMA cannot activate
CARD9 signaling. To further explore the innate immune response
induced by TDM or MA in vivo, we intraperitoneally injected the
TDM or fMA emulsion into mice and measured the level of
MCP-1 and TNF, and Nos2 mRNA levels, as well as the number
of recruited inﬂammatory cells, induced in the peritoneal cavities.
We detected MCP-1 in peritoneal lavages following respective
fMA and TDM administrations at similar levels, with peak MCP1 levels observed at 4 and 24 h post injection, respectively
(Fig. 5d). However, TNF production and Nos2 mRNA expression
were induced only by TDM but not fMA (Fig. 5d), which was
consistent with results from the in vitro-stimulated macrophages
(Fig. 4). Moreover, we observed that TDM recruited substantial
numbers of macrophages [CD11b+Ly6G−F4/80low small peritoneal macrophages (SPMs)], Supplementary Fig. 5b) and neutrophils (CD11b+Ly6G+F4/80−, Supplementary Fig. 4b) to the
cavity, whereas fMA recruited comparable numbers of macrophages as TDM, but fewer neutrophils only immediately after
administration (Fig. 5e). Importantly, MCP-1 level (Fig. 5f)
and the number of recruited cells (Fig. 5g) induced by fMA in
Trem2−/− mice were almost the same as those induced by the
control vehicle administration, indicating that the fMA-induced
inﬂammation was dependent on TREM2.
To investigate the phenotype of TDM- or fMA-induced
macrophages, we examined the expression of the inﬂammatory
M1-macrophage markers iNOS and CD38 (ref. 64) in the
recruited macrophages (Fig. 5h and Supplementary Fig. 5c).
Intraperitoneal administration of TDM and fMA recruited
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Fig. 4 Distinct lipid recognition and macrophage activation through Mincle and TREM2. a–c Peritoneal macrophages from wild-type (WT), Trem2−/−, or
Clec4e−/− mice (a), WT, Tyrobp−/−, or Fcer1g−/− mice (b), or WT or Card9−/− mice (c) were stimulated with the indicated amounts of TDM, GMM,
GroMM, or fMA coated on the plates or with LPS (100 ng/ml) for 24 h. WT cells were stimulated in the presence or absence of the Syk inhibitor BAY613606 (BAY) (c). MCP-1 and TNF production in the culture supernatant was measured by ELISA. Data are presented as the mean ± SEM of triplicate
assays and are representative of three independent experiments. The statistical signiﬁcance was calculated by two-way ANOVA followed by Bonferroni’s
test. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source data ﬁle.
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comparable numbers of macrophages to the cavity (Fig. 5i);
however, although TDM-induced macrophages exhibited a
CD38highiNOS+ phenotype (Fig. 5j), those induced by fMA had
reduced CD38 expression and were negative for iNOS (Fig. 5k).
This phenotype resembles a previously reported phenotype
associated with permissive macrophages that are recruited by a
8

subset of pathogenic mycobacteria expressing the virulence lipids
PDIM and PGL in an MCP-1- and CCR2-dependent manner,
and provide a niche for mycobacterial propagation21,65.
Collectively, these results suggested that triggering of the
Mincle–CARD9 pathway elicited lung granuloma formation and
recruited M1-type mycobactericidal macrophages producing TNF

NATURE COMMUNICATIONS | (2021)12:2299 | https://doi.org/10.1038/s41467-021-22620-3 | www.nature.com/naturecommunications

NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-22620-3

ARTICLE

Fig. 5 Triggering of TREM2 by MA induces the permissive macrophages. a, b BMDMs were stimulated for 24 h with the indicated amount of TDM or fMA
in the presence of 10 ng/ml IFN-γ (a), 1 μg of TDM with or without the indicated amounts of a TNF-blocking antibody (αTNF Ab) or an isotype-matched
control antibody (Control Ab) (b), or 1 μg of fMA with or without recombinant TNF (rTNF) (b). NO production was determined by Griess assay. Data
represent as the mean ± SEM of triplicate assays from three independent experiments. The statistical signiﬁcance was calculated by one-way ANOVA
followed by Bonferroni’s test. **p < 0.01, ***p < 0.001, n.s. not signiﬁcant. c Representative images of the hematoxylin and eosin-stained lungs from WT,
Clec4e−/−, or Card9−/− mice at day 7 after intravenous injection of 50 μg TDM or 250 μg fMA emulsion. The images are representative of two independent
experiments. Scale bars: 0.1 mm. d–f Peritoneal lavages were collected at 4, 24, and 72 h after intraperitoneally injection of 500 μg fMA or 100 μg TDM
emulsion to WT mice (n = 4). MCP-1 and TNF concentrations in the lavages were measured by ELISA, and Nos2 mRNA levels were measured by quantitative
RT-PCR. e Flow cytometric analysis of peritoneal neutrophils (CD11b+Ly6G+F4/80−) and monocyte-derived macrophages (CD11b+Ly6G−F4/80low SPMs)
from WT mice (n = 4) at 48 and 72 h post injection of MA or TDM emulsions as in d. f, g WT or Trem2−/− mice were injected intraperitoneally with fMA or
control (vehicle) emulsion. The concentrations of MCP-1 (control, n = 4; fMA, n = 6; at 4 h) and TNF (n = 4; at 72 h) in the peritoneal lavages was measured
by ELISA (f). Peritoneal exudate cells (n = 4; at 72 h) was analyzed as in e and g. h–k WT mice were injected intraperitoneally with TDM, fMA, or control
(vehicle) emulsion, and inﬁltrated macrophages at days 1, 2, and 3 were analyzed by ﬂow cytometry for the expression of CD38 and iNOS (h). The numbers
of total recruited monocyte-derived macrophages (CD11b+Ly6C+F4/80+) (i), the M1 macrophages (CD11b+Ly6C+F4/80+CD38highNOS+) (j), and
permissive macrophages (CD11b+Ly6C+F4/80+CD38dullNOS−) (k) at day 3 are shown. Data in d–k represent as the mean ± SEM from at least three
independent experiments. The statistical signiﬁcance was calculated by two-way ANOVA followed by Bonferroni’s test (f–g) or by two-tailed unpaired t test
(i–k). *p < 0.05, **p < 0.01, ***p < 0.001, n.s. not signiﬁcant. Source data are provided as a Source data ﬁle.

and NO, whereas TREM2 activation recruited mycobacteriumpermissive macrophages lacking TNF and NO production.
TREM2 deﬁciency exacerbates Mincle-induced inﬂammation.
To investigate the relevance of TREM2 inhibition of Mincleinduced macrophage activation in vivo, we assessed the impact of
TREM2 deﬁciency on tissue inﬂammation induced by TDM
administration. Intraperitoneal injection of TDM emulsion into
Trem2−/− mice resulted in signiﬁcantly higher levels of TNF and
MCP-1 production and increased Nos2 mRNA expression
(Fig. 6a), as well as higher numbers of macrophages and neutrophils to the peritoneal cavities (Fig. 6b), as compared to those
observed in WT mice. Intravenous injection of the TDM emulsion into mice induces lung swelling (increased lung weight
index: LWI) and thymic atrophy (decreased thymic weight index:
TWI) dependent on the Mincle–FcRγ pathway30. We observed
that Trem2−/− mice displayed signiﬁcantly higher LWI and lower
TWI than WT mice following TDM injection (Fig. 6c). Histopathological analysis of the lungs revealed that the granulomatous
lesions were markedly more prominent in Trem2−/− mice
(Fig. 6d). In addition, speciﬁc pathological features in the form of
prominent vasculitis and edema, indicating accelerated inﬂammation, were observed in the lungs of Trem2−/− but not WT
mice (Supplementary Fig. 6). Consistent with these results, the
levels of TNF and MCP-1 production and Nos2 mRNA expression in the inﬂamed lungs were signiﬁcantly higher in Trem2−/−
mice than in WT mice (Fig. 6e). These results suggested that
TREM2 suppressed Mincle-induced inﬂammation in vivo.
TREM2 deﬁciency accelerates the clearance of mycobacterial
infection. Since our data suggested a suppressive role for TREM2
in the microbicidal innate immune response via Mincle, we
investigated the impact of TREM2 deﬁciency on the clearance of
mycobacterial infection. First, we infected WT and Trem2−/−
BMDMs with M. bovis BCG in vitro, and assessed NO production
and mycobacterial killing in the macrophages. NO production in
Trem2−/− BMDMs was signiﬁcantly higher than in WT BMDMs
(Fig. 7a). Accordingly, the number of intracellular BCG colonyforming units (CFUs) was signiﬁcantly lower in Trem2−/−
BMDMs than in WT BMDMs (Fig. 7b). TREM2 deﬁciency
did snot affect the phagocytic activity of BMDMs against M. bovis
BCG (Supplementary Fig. 7), suggesting that the lower bacterial
CFUs in Trem2−/− BMDMs was likely resulted from the
enhanced bactericidal activity, but not from an impaired
phagocytosis.

Next, to investigate the relevance of this observation in vivo, we
have intratracheally infected WT and Trem2−/− mice with M.
bovis BCG, and examined the bacterial burden and inﬂammatory
mediators in the infected lungs at days 3 and 14 after infection.
The bacterial burden in the lungs at day 14, but not day 3, was
signiﬁcantly lower in Trem2−/− mice than in WT mice (Fig. 7c).
Analyses of the cytokine production (MCP-1 and TNF),
macrophage inﬁltration (estimated by Adgre1 (F4/80) expression), and Nos2 (iNOS) induction in the infected lungs detected a
higher expression of Ccl2 (MCP-1; Fig. 7d), Adgre1 (Fig. 7e), and
Nos2 (Fig. 7f) in Trem2−/− mice than in WT mice at day 3 after
infection. TNF upregulation detected neither in the lungs of WT
nor Trem2−/− mice in any time points (Supplementary Fig. 8a).
While in the day 14 lungs, the expression of Ccl2 and Adgre1 was
rather lower in Trem2−/− mice than in WT mice though Nos2
expression was comparable, which was assumed to reﬂect the
subsided inﬂammation by the accelerated bacterial clearance in
the lungs of Trem2−/− mice at this time point. Similarly, a higher
inﬂammatory response at early time point and a lower bacterial
CFUs at later time points in Trem2−/− mice than in WT mice
were observed, as well in an intraperitoneal M. bovis BCG
infection (Supplementary Fig. 8b–e). To examine the impact of
TREM2 deﬁciency on T-cell immunity against mycobacteria, we
collected mediastinal lymph node cells from WT and Trem2−/−
mice at day 14 after the intratracheal infection, and stimulated
them with the mycobacterial antigen puriﬁed protein derivative
(PPD) to analyze their production of interferon (IFN)-γ and IL17A. We observed that TREM2 deﬁciency did not signiﬁcantly
affected the production of these cytokines by the lymph node cells
(Supplementary Fig. 8f), suggesting that the accelerated bacterial
clearance in the Trem2−/− lungs was likely resulted from the
enhanced bactericidal responses by macrophages in the early
stage of infection rather than from the subsequent T-cellmediated immunity. This hypothesis might be supported by the
data that neither the addition of MA (Supplementary Fig. 8g) nor
TREM2 deﬁciency (Supplementary Fig. 8f, h) signiﬁcantly
affected T-cell recall responses in mice vaccinated with complete
Freund’s adjuvant (CFA) that contains mycobacterial components. Collectively, TREM2 plays a signiﬁcant role in regulating
the early bactericidal innate immune responses during mycobacterial infection.
Discussion
In the present study, we identiﬁed the DAP12-associated TREM2
as a receptor for mycobacteria by the screening using the ITAMcoupled receptor-Fc fusion protein library. TREM2 is expressed
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Fig. 6 TREM2 deﬁciency exacerbates Mincle-induced inﬂammation. a, b WT or Trem2−/− mice (n = 4) were intraperitoneally injected with 100 μg TDM
or control (vehicle) emulsion. TNF and MCP-1 in the peritoneal lavages were measured by ELISA and Nos2 mRNA levels in the peritoneal cells were
measured by qRT-PCR at 24 h post injection (a). The numbers of macrophages and neutrophils in the peritoneal cavities at 72 h post injection were
analyzed by ﬂow cytometry (b). c–e WT or Trem2−/− mice (n = 5) were intravenously injected with 50 μg TDM or control emulsion, and the lungs and
thymuses were collected at day 7 after the injection. LWI and TWI are shown (c). Representative hematoxylin and eosin-stained sections of lung lobes
from WT and Trem2−/− mice (scale bars: upper panels, 1 mm; lower panels, 0.1 mm) are shown (d). Cytokine concentration in lung homogenates was
measured by ELISA, and Nos2 mRNA levels in the lungs were measured by qRT-PCR (e). Data in a–c and e are presented as mean ± SEM and are
representative of at least two independent experiments. The statistical signiﬁcance was calculated by two-way ANOVA followed by Bonferroni’s test (a, b)
or by two-tailed unpaired t test (c, e). *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a Source data ﬁle.

on various myeloid cells, including macrophages and
microglia66, and Trem2 deﬁciency is reportedly related to various
neurodegenerative diseases. Homozygous loss-of-function
mutations of Trem2 or Tyrobp (Dap12) cause Nasu-Hakola
disease accompanied by demyelination and axonal loss67,68.
Single-nucleotide polymorphisms, including the TREM2 R47H
variant, increase the risk of dementia, including frontotemporal
lobar degeneration, Parkinson’s disease, Alzheimer’s disease, and
amyotrophic lateral sclerosis46–49. These genetic associations
highlight the physiological importance of TREM2 and its ligand
recognition. Previous reports indicate that TREM2 binds to
anionic ligands of bacteria69, lipo-oligosaccharide (LOS) of
Neisseria gonorrhoeae70,71, several brain lipids associated with
10

ﬁbrillar amyloid β (ref. 45), and apolipoproteins72. Although
these ligands have been identiﬁed, ligand structures prerequisites
for TREM2 recognition remain unknown. Here, we identiﬁed
MA-containing lipids as TREM2 ligands and found that their
branched alkyl chains are required for TREM2 recognition via a
structure–activity relationship analysis. The removal of branched
alkyl chains from LOS by O-deacetylation diminishes
TREM2–LOS interaction71, which implicates the lipid moiety of
LOS in the interaction with TREM2. In addition, TREM2 ligands
in the brain include phospholipids or sphingolipids carrying
branched alkyl chains45; therefore, our ﬁndings agree with previous results and might offer insight into future searches for
unknown TREM2 ligands.
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Fig. 7 TREM2 deﬁciency accelerates the clearance of mycobacterial infection. a, b WT or Trem2−/− BMDMs were infected in vitro with M. bovis BCG
(MOI 10) for 4 h. After washing, the cells were further cultured for 24 h, and nitrite concentration in the culture supernatant was measured by Griess assay
(a). The cells were collected, lysed, and CFUs of M. bovis BCG were counted (b). The statistical signiﬁcance was calculated by two-tailed unpaired t test. c–f
WT or Trem2 −/− mice (day 3, n = 5; day 14, n = 7) were infected intratracheally with 7.5 × 106 CFU of M. bovis BCG. The lung tissues were collected at
days 3 and 14 after infection, homogenized, and CFU were determined (c). The expressions of Ccl2, Adgre1, and Nos2 in the lungs from uninfected control
(n = 5) and infected mice were analyzed by qRT-PCR (d–f). Data are presented as the mean ± SEM and are representative of two independent
experiments. The statistical signiﬁcance was calculated by two-tailed unpaired t test. *p < 0.05, **p < 0.01. Source data are provided as a Source data ﬁle.

We found that macrophage activation by glycosylated versus
non-glycosylated MA lipids resulted in different patterns of
response with different receptor requirements. While glycosylated
MAs were recognized by Mincle, and induced the production of
MCP-1, TNF, and NO, non-glycosylated MAs were recognized by
TREM2 and induced only MCP-1 production. A previous report
showed that human Mincle, but not mouse Mincle could recognize GroMM and induces TNF production in primary human
macrophages73, suggesting that the range of structures of MA
ligands recognized by Mincle might differ between humans and
mice. Nevertheless, Hattori et al. showed in this report that the
binding afﬁnity of human Mincle to GroMM was ~100-fold lower
than that to TDM, indicating the importance of the sugar moiety
for the recognition by Mincle, regardless of species. Importantly,
our data showed that mouse Mincle was also capable of binding
to GroMM at higher concentrations, although it was not essential
for macrophage response to GroMM. Future studies should
clarify the contributions of TREM2 and Mincle to recognition of
MA-containing lipids in humans.
MCP-1 plays a role in the early stages of Mtb infection53,54. In
addition, higher levels of MCP-1 production are associated with
greater severity of TB in human patients74. The polymorphism of
at position −2518 the MCP-1 promoter is associated with TB
susceptibility75,76, and the odds of developing TB is 2.3- to 5.5fold higher in patients with MCP-1 genotypes AG and GG
relative to those with the AA genotype. Patients carrying the AG
or GG genotype harbor extremely high concentrations of MCP-1,
which inhibit the expression of IL-12 (ref. 76), suggesting that
elevated MCP-1 production and lower inﬂammatory cytokine
levels promote TB development. This is a similar phenomenon to
that observed following TREM2 recognition of non-glycosylated
MAs in the present study. Mycobacterial cell wall components,
PDIM and PGL, enhance infectivity by selective induction of
MCP-1 for the recruitment of the permissive macrophages77.

These ﬁndings indicate that exclusive production of MCP-1 via
TREM2 is presumably beneﬁcial to mycobacteria.
The recruitment of permissive macrophages and inhibition of
Mincle–FcRγ–CARD9 signaling are key functions of TREM2.
Here, we found that TREM2/DAP12 signaling speciﬁcally
inhibited Mincle–FcRγ–CARD9 signaling, but not TLR signaling.
However, previous reports show that TREM2 deﬁciency enhances
cytokine production induced by TLRs78,79. Although the reason
for this discrepancy is unknown, upregulated signaling via Mincle
might be responsible for the enhanced TLR response. Because
Mincle recognizes damaged cell-derived endogenous ligands80,81,
Mincle expression induced by TLR stimulation30 might subsequently amplify the TLR response82 depending on cell condition.
Alternatively, TREM2 binding to TDM (Fig. 3) but not TLR
ligands could generate signiﬁcant inhibitory signals upon TDM
stimulation; therefore, TREM2 deﬁciency might result in more
obvious effects on the signaling via Mincle than that via TLRs.
The composition of MA-containing lipids dynamically changes
in response to the external environment. TDM is a major glycosylated MA in the mycobacterial cell wall in culture, but in the
host under glucose-rich condition, TDM synthesis is downregulated, and GMM is produced by mycolytransferases using
host-derived glucose7. Because glycosylated MAs exhibit potent
adjuvant activity83, the presence of these lipids preferentially
activates the immune response through Mincle to eliminate
mycobacteria. Lipid composition differs in latent mycobacterial
infections. GroMM might be associated with latent mycobacteria,
given that GroMM-reactive T cells are observed only in latent but
not active TB cases15,73. In addition, levels of glycosylated MAs
decrease in Mtb in a nonreplicating dormant-like state6. Therefore, we speculate that the recognition of latent mycobacterial cell
walls by TREM2 might lead to the recruitment of permissive
macrophages, thereby promoting chronic infection (Supplementary Fig. 9).
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Macrophages or microglia phagocytize bacteria or apoptotic
cell debris through TREM2 (refs. 70,84–86). Macrophages are
roughly classiﬁed into M1 and M2 subtypes that exert opposite
effects on the inﬂammatory response87. M1 macrophages are proinﬂammatory, whereas M2 macrophages are anti-inﬂammatory
and exhibit phagocytic activity to promote tissue repair and
homeostasis. Unlike FcRγ-coupled mycobacterial receptors
including Mincle, TREM2–DAP12 signaling seemingly confers
M2-like anti-inﬂammatory properties on macrophages. Indeed,
IL-4, which skews macrophage polarization toward M2, induces
TREM2 expression in macrophages79. In addition, TREM2 deﬁciency impairs wound healing of colonic mucosal injures
accompanied by diminished M2 differentiation and increased
TNF and IFN-γ production88. Moreover, TREM2 plays an
important role in maintaining homeostasis in the brain by
clearance of dead cells or amyloid-β through brain-lipid
recognition84. Therefore, mycobacteria presumably harness the
functions of TREM2 by stimulating TREM2 with MA-containing
lipids to gain niches suitable for their propagation.
Collectively, our data suggest that TREM2–DAP12 signal activation by non-glycosylated MAs, which are associated with virulent or
latent mycobacterial infections, recruits permissive macrophages and
suppress the mycobactericidal immune response induced by glycosylated MAs through Mincle–FcRγ–CARD9 signaling. Therefore,
this study elucidated a mechanism by which mycobacteria control the
host immune response by stimulating a host regulatory receptor with
their speciﬁc cell wall lipids. Our ﬁndings suggest that targeting the
TREM2–DAP12 pathway might represent a novel therapeutic
intervention to control mycobacterial diseases.

extra no spots and for MADI-TOF mass spectrometry analyses to conﬁrm the
identity of the lipids.
Mice. All mice used in this study were between the ages of 8–15 weeks. WT
C57BL/6 mice were purchased from Kyudo co. Trem2−/−, Card9−/−, Clec4e−/−,
Tyrobp−/−, and Fcer1g−/− mice were generated previously27,79,91–93. All knockout
mice were C57BL/6 genetic background. Clec4e−/−, Tyrobp−/−, and Fcer1g−/−
mice were kindly provided by Prof. Shizuo Akira (Osaka University), Prof.
Toshiyuki Takai (Tohoku University), and Dr. Takashi Saito (RIKEN), respectively.
All mice were maintained at the animal facility on Institute of Laboratory Animal
Science Research Support Center Kagoshima University in a speciﬁc pathogen-free
conditions room with a 12-h light/dark cycle at 22 ± 1 °C and 50 ± 10% humidity.
All experiments using mice were approved by the Institutional Animal Research
Committee of Kagoshima University and animals were treated in accordance with
the ethical guidelines of Kagoshima University. Both male and female mice were
used in this study but sex-matched mice were used for the comparison between
groups in the same experiment.
ITAM-coupled receptor-Fc preparation. Human IgG1 Fc region was integrated
into AccI site of pDisplay (Invitrogen #V660-20). The ectodomain of Clec2, Mincle,
Clec9a, MGL-1, SIGNR1, SIGNR3, DCAR, Clec5a, DC-SIGN (human), TREM1,
TREM2, TREM3, LMIR2, LMIR4, LMIR5, LMIR7, LMIR7, and LMIR8 (all from
mouse origin except for DC-SIGN) were PCR ampliﬁed with the primers in
Supplementary Table 1 using cDNA clones (purchased from DNAFORM) as
templates, and were inserted into the upstream of the human IgG1 Fc region inframe in pDisplay. pDisplay-mouse Dectin-1-Fc (kindly provided by Prof. Naohito
Ohno, Tokyo University of Pharmacy and Life Sciences) and pME18S-mouse
Dectin-2-Fc80 were used for the following Dectin-1-Fc and Dectin-2-fc expression,
respectively. The plasmids were transfected into Freestyle 293 cells (Thermo Fisher
Scientiﬁc #R79007) using Freestyle MAX reagent (Invitrogen #16447-100), and
then cultured according to the manufacturer’s instruction. The culture supernatants were collected and then concentrated ~20 times by using VIVASPIN 20
MWCO 30 kDa (Sartorius Stedim Biotech #VS2022). These concentrated supernatants were used in the screening for proteins binding to mycobacteria. For the
plate-coated lipid binding assay, TREM2- and Mincle-Fc fusion proteins were
puriﬁed by using protein G columns, as descried previously80.

Methods
Reagents. MAs from M. bovis BCG was prepared as described below. TDM
(#T3034), LPS (#L3024), ABG (#10830), PA (#P0500), and HBA (#166898) were
purchased from Sigma-Aldrich. Poly (I:C; #tlrl-picw), CpG-ODN (#tlrl-1585),
Pam3CSK4 (#tlrl-pms) were purchased from InvivoGen. Oxidized (OX)-zymosan
was kindly provided by Prof. Naohito Ohno (Tokyo University of Pharmacy and
Life Sciences). MA from R. equi was kindly provided by Dr. Jun Miyazaki (Tsukuba
University). LAM (#02449-61) was purchased from Nakalai tesque. THA
(#T292210) was purchased from Wako pure chemical industries.
Preparation of MA-containing lipids. Total lipids from mycobacteria were prepared as described previously89. Bireﬂy, bacterial cells were extracted at 100 mg/ml
in chloroform:methanol (C/M) (2:1, v/v) for 1 h at room temperature. After the
centrifugation, the supernatant was ﬁltered and evaporated in vacuo to weigh the
recovered amounts of the total lipids. GMM and GroMM were prepared as
described previously7,16,90. For GMM preparation, the total lipids dissolved in C/M
(2:1) were added with 20 volumes of ice-cold acetone and incubated for 30 min on
ice. After centrifugation, the pellet was washed with ice-cold acetone, dissolved
with C/M (2:1), and fractionated by TLC (Analtech #Z26551) with chloroform/
methanol/acetone/acetic acid (90:10:10:1, v/v), followed by fractionated with
chloroform/acetone/methanol/water (50:60:2.5:0.6, v/v). The spot corresponding to
GMM was scraped off the silica gel plate and extracted with C/M (2:1), dried, and
rinsed several times with methanol at room temperature to remove residual contamination of glycopeptidolipids and phospholipids. For GroMM preparation, the
total lipids extracted from the bacteria cultured in 7H10 medium containing 10%
of glycerol were fractioned by two cycle of TLC with chloroform/ethyl acetone (5:1,
v/v). The lipid spots were visualized with iodine vapor, and the spot corresponding
to GroMM was scraped off the silica gel plate, followed by elution with C/M (2:1).
fMAs were isolated from M. bovis BCG (Tokyo 172 strain, Japan BCG laboratory).
The BCG cells were suspended in 85% tetrahydrofuran (THF)/water solution
under a nitrogen atmosphere, followed by reﬂux with stirring for 1 h. The cell
suspension was ﬁltrated under pressure and washed with 75% THF/water solution.
The residue was resuspended in 75% THF/water solution under a nitrogen
atmosphere, followed by reﬂux with stirring for 1 h. The suspension was ﬁltrated
under pressure and washed with 75% THF/water solution three times and with
methanol twice. Then, the bacterial cells were suspended in 50% 2-propanol/water
solution containing 10% potassium hydroxide, followed by reﬂux with stirring for
2 h to complete alkaline hydrolysis of MA ester. After the reﬂuxing, the suspension
was cooled down on ice, and acidiﬁed with 6 M hydrochloric acid. The reaction
mixture was extracted twice with n-heptane, and the n-heptane fraction was
washed twice with water and then twice with 90% ethanol/water. Finally, the nheptane fraction was concentrated in vacuo to obtain puriﬁed MAs. The ﬁnal
preparations of GMM, GroMM, and fMA were applied for TLC to conﬁrm no
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Fractionation of mycobacteria. Ten mg of freeze-dried heat-killed Mtb H37Ra
(Difco) was extracted with 500 μl of chloroform/methanol (2:1, v/v). After collecting the supernatant (sup fraction) by centrifugation, the de-lipidated precipitate
(ppt fraction) was dried and resuspended with 500 μl (the same volume as the
original extract) of PBS. While, water was added to the sup fraction so that the
chloroform/methanol/water ratio was 8:4:3 (v/v), and further fractionated into the
lipid-soluble (C:M) and the water-soluble (M:W) fractions. The C:M and M:W
fractions were ﬁlled-up to 500 μl with chloroform/methanol (2:1, v/v) and
methanol, respectively. Nontreated Mtb H37Ra was also dissolved in 500 μl of PBS.
For the reporter assay, the nontreat and ppt fractions were serially diluted by four
times with PBS and the same volume of these suspensions (μl/well) was directly
added to the reporter cell culture in 96-well plates. The C:M and M:W fractions
were serially diluted by four times with isopropanol, and the same volume of these
solutions was added to the wells of 96-well plates and coated on the bottoms by
solvent evaporation in a hood, followed by adding the reporter cells. The reporter
cell assay was performed as below.
2B4-NFAT-GFP reporter cells. For the construction of DAP12 expression plasmid, SLAM signal sequence-FLAG-mouse DAP12 cassette was PCR ampliﬁed from
pMX-IRES-GFP-FLAG-DAP12 (kindly provided by Dr. Takashi Saito, RIKEN)
with the following primers: 5′-ACGCGTCGACGCCGCCACCATGGATCCCAA
AGGATCCCT-3′ and 5′-AAGGAAAAAAGCGGCCGCCAGTGTGATGGA-3′.
The ampliﬁed DNA was then digested with SalI and NotI, and cloned into XhoI
and NotI sites of pMX-IRES-rCD2 to obtain pMX-IRES-rCD2-FLAG-DAP12. For
the construction of TREM1 and TREM2 expression vectors, the coding sequences
of mouse TREM1 (amino acids 21–230) and mouse TREM2 (amino acids 19–227)
without signal sequences were PCR ampliﬁed with the primers: 5′-TACCCATAC
GATGTTCCAGATTACGCTGCCATTGTTCTAGAG-3′ and 5′-AAGGAAAAAA
GCCGCTCATCCAAATGTCCT-3′; 5′-TACCCATACGATGTTCCAGATTACGC
TCTCAACACCACGGTG-3′; and 5′-AAGGAAAAAAGCGGCCGCTCACGTAC
CTCCGGG-3′, respectively. SLAM signal sequence fused with HA was ampliﬁed
by PCR using the primers: 5′-GAAGATCTGCCGCCACCATGAAAGACGACTT
T-3′ and 5′-AGCGTAATCTGGAACATCGTATGGGTACACACCTCCACCTG
T-3′ from pMX-IRES-rCD2-FLAG-DAP12. Then, the SLAM signal sequence-HA
cassette was fused to TREM1 or TREM2 PCR products by subsequent PCR
ampliﬁcation, and cloned into pMX-IRES-hCD8 to obtain pMX-IRES-hCD8-HATREM1 and pMX-IRES-hCD8-HA-TREM2. pMX plamids were retrovirally
transfected into 2B4-NFAT-GFP reporter cells (kindly provided by Dr. Takashi
Saito, RIKEN), as described previously80,94. Breiﬂy, pMX-IRES-rCD2-FLAGDAP12 was transfected into a retroviral packaging cell line, Phoenix (kindly provided by Dr. Takashi Saito, RIKEN), with Lipofectamine LTX and Plus Reagent
(Invitrogen #15338-100). The culture supernatants of Phoenix were collected after
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24, 48, and 72 h, pooled, and centrifuged overnight 8000 × g to concentrate the
virus. The concentrated viruses were added to 2B4-NFAT-GFP cells with 8 μg/ml
polybrene (Nacalai tesque #12996-81) and centrifuged at 780 × g for 1 h for
infection. The transfected cells were stained with PE-conjugated anti-rat CD2
antibody (Biolegend #210315) and anti-PE Microbeads (Miltenyi Biotec #130-048801), and then puriﬁed by MACS (Miltenyi Biotec #130-042-201). The purifed
2B4-NFAT-GFP cells expressing DAP12 were cloned by serial dilution. Then,
pMX-IRES-hCD8-HA-TREM1 or pMX-IRES-hCD8-HA-TREM2 were retrovirally
transfected in the same way into 2B4-NFAT-GFP cells expressing DAP12 to
produce 2B4-NFAT-GFP expressing DAP12 and TREM1 or TREM2, respectively.
The transfected cells were stained with APC-conjugated antihuman CD8 antibody
(Biolegend #300911) and anti-APC Microbeads (Miltenyi Biotec #130-090-855),
and then puriﬁed by MACS. The puriﬁed cells were cloned by serial dilution. The
R47H mutation in TREM2 was generated by KOD-Plus-Mutagenesis Kit
(TOYOBO #SMK-101) using pMX-IRES-hCD8-HA-TREM2 as a template. 2B4NFAT-GFP cells expressing FcRγ and Mincle were generated previously as
described80. For the reporter assay, 5 × 104 reporter cells in 96-well plate were
incubated with mycobacteria, soluble PAMPs, or plate-coated lipids for 24 h and
then data were collected by Cytoﬂex ﬂow cytometer (BECKMAN COULTER)
using CytExpert software version 2.3. Flow cytometry data were analyzed using
FlowJo software version 10.5.3 (BD). Percent increase was calculated by dividing
GFP MFI values after stimulation by those before stimulation.

Screening for ITAM-coupled receptors binding to mycobacteria. Heat-killed
Mtb H37Rv, Mtb H37Ra (Difco #231141), or M. bovis BCG were incubated with
20 μg/ml of ITAM-coupled receptor-Fc fusion proteins or control Fc fragment
protein in RPMI 1640 medium for 1 h on ice. After two times washing with the
medium, the mycobacterial cells were incubated with ﬂuorescein isothiocyanate
(FITC)-conjugated antihuman IgG secondary antibody (Jackson ImmunoResearch
#709-095-149) for 30 min on ice. After a wash, the ﬂuorescence intensity was
analyzed by ﬂow cytometer as above. The receptors that showed higher ﬂuorescence intensities than the control values were judged as positive for binding.

Plate-coated lipid binding assay. The lipids (MA, TDM, TDB, PA, THA, GMM,
GroMM, and HBA) were dissolved in chloroform at 1 mg/ml, and then diluted
with isopropanol to the working concentrations. Lipid binding assay was performed as described previously95. Brieﬂy, 0.5 μg/well of fMA, GroMM, GMM, and
TDM were coated on ELISA plates, and then incubated with 0.24–1000 nM puriﬁed Mincle-Fc or TREM2-Fc proteins in TSM buffer (20 mM Tris–HCl, 150 mM
NaCl, 1 mM CaCl2, 2 mM MgCl2, pH 7.0) for 2 h at room temperature. The plates
were washed four times with 150 μl of TSM buffer, and then incubated with
antihuman IgG HRP secondary antibodies (abcam #ab6759) for 1 h at room
temperature. The binding was detected by colorimetric assay using TMB substrate
(Sumitomo Bakelite #ML-1120T) and the absorbance at 450 nm was measured by
VERSAMax microplate reader, using SoftMaxPro software (Molecular Devices).

In vitro macrophage stimulation. Peritoneal macrophages were prepared as
described previously96. Brieﬂy, 2 ml of 4% thioglycollate (Difco #225640) solution
was intraperitoneally injected into mice. Five days after the injection, peritoneal
cells were collected by washing the peritoneum cavity with 5 ml of RPMI 1640
medium containing 10% FCS and 2-mercaptoethanol (RPMI-10). The collected
cells were cultured overnight in RPMI-10 and then the adherent cells were used for
assays. BMDMs were prepared as described previously27. Brieﬂy, bone marrow
cells collected from WT, Trem2−/−, Tyrobp−/−, or Clex4e−/− mice were cultured
in RPMI-10 in the presence of 25 ng of recombinant murine M-CSF (PeproTech
#AF-315-02) for 3 days, and then the adherent cells were collected as BMDMs. For
in vitro cell stimulation, the lipid solutions were added into the 96-well ﬂat bottom
plates at 20 μl/well and then the solvent was completely evaporated in a hood
before plating macrophages30. A total of 1 × 105 cells/well were stimulated with
plate-coated lipids or TLR ligands in RPMI-10. The culture supernatants after 24-h
culture were collected and the concentrations of TNF (eBioscience #88-7324-88),
IL-6 (eBioscience #88-7024-88), IL-12p40 (Biolegend #431604), IL-10 (Biolegend
#431411), and MCP-1 (Biolegend #432701) were analyzed by ELISA kits, according
to manufacturer’s instructions. For Syk inhibition, cells were incubated with 1 μM
BAY-613606 (Calbiochem #574714) for 30 min prior to the stimulation.

Measurement of NO production. BMDMs were stimulated in RPMI-10 with 0.1
or 1.0 μg per plate of plate-coated MA or TDM in the presence of 10 ng/ml of
recombinant IFN-γ for 24 h. For the assessment of TNF involvement in NO
production, carrier-free recombinant mouse TNF (Biolegend #575202), LEAF
puriﬁed anti-mouse TNF-α antibody (MP6-XT22; BioLegend #506331), or LEAF
puriﬁed Rat IgG1 κ Isotype Ctrl antibody (BioLegend #400457) were added to the
culture. The culture supernatants were collected and mixed with Griess reagent (1%
sulfanilamide, 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride, and 2.5%
phosphoric acid) at a 1:1 ratio, reacted for 10 min, and the absorbance at 550 nm
was measured by a VERSAMax microplate reader using SoftMaxPro software. The
nitrite concentration was calculated according to the standard curve.
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Quantitative real-time PCR. Total RNA was isolated from cells using SepasolRNA I Super G RNA-isolation kit (Nacalai Tesque #09379). After the removal of
DNA contamination by DNase I (Nippon Gene #312-05951), the total RNA was
reverse-transcribed with ReverTra Ace qPCR RT Master Mix (TOYOBO #FSQ201) to synthesize cDNA. Quantitative real-time PCR (qRT-PCR) was performed
with THUNDERBIRD SYBR qPCR Mix (TOYOBO #QPS-201), using StepOnePlus
and StepOne Software version 2.3 (Thermo ﬁsher scientiﬁc). Sequences of the
speciﬁc primer sets used in this PCR were listed in Supplementary Table 2. The
relative expression levels of the genes were calculated by ΔΔCt method normalized
by Gapdh.
MA and TDM emulsions for i.p. administration. A total of 10 mg MA or 2 mg
TDM was dissolved in 1 ml of Bayol F (SERVA Electrophoresis #14500.01) at 64 °
C, then mixed with 1 ml of PBS using a handy homogenizer (RELIEF). A total of
100 μl of the emulsion was intraperitoneally injected into WT or Trem2−/− mice.
The emulsion without lipids was injected as a vehicle control. Peritoneal lavages
were collected by washing the peritoneum cavity with RPMI-10. Concentration of
cytokine in the lavage was measured by ELISA kit, as described above.
TDM emulsion for i.v. administration. TDM emulsion was prepared as described
previously30. Brieﬂy, 1 mg of TDM was dissolved in 180 μl of Bayol F at 64 °C, then
mix with 1.8 ml of 1.1% Tween 80/0.9% NaCl solution to make emulsion. A total of
100 μl of the emulsion including 50 μg of TDM was intravenously injected into WT
and Trem2−/− mice. At day 7, the thymuses, lungs, and body weights were measured and the thymus or lung weights were divided by body weights to calculate
lung or thymus weight index, respectively. The left lobes were then ﬁxed in 4%
paraformaldehyde, and embedded in parafﬁn and stained with hematoxylin and
eosin solution. The slides were analyzed by All-in-One ﬂuorescence microscope
BZ-X700 using BZ-H4XD software (KEYENCE). The rest of lung tissues were
homogenized by gentleMACS (Miltenyi Biotec), running program lung_01, followed by incubation for 35 min at 37 °C in PBS containing 0.2 mg/ml Liberase Tm
(Roche #5401119001) and 25 μg/ml DNase I (Roche #11 184 932 001), then program lung_02, as described previously97, and the concentration of cytokines in
homogenates were measured by ELISA kit, as described above.
Flow cytometry. For the analysis of inﬁltrated neutrophils and macrophages, cells
in the peritoneal lavage were stained with FITC-conjugated anti-CD11b antibody
(M1/70, eBioscience #11-0112-41), PE-conjugated anti-Ly6G antibody (1A8,
eBioscience #12-9668-82), and APC-conjugated anti-F4/80 antibody (BM8.1,
TONBO biosciences #20-4801) after the Fc-blocking with anti-CD16/CD32 antibody (2.4G2, TONBO biosciences #70-0161). For the intracellular iNOS (NOS2)
staining, the cells after the Fc-blocking were stained with PE-Cy7-conjugated antiLy6C (HK1.4, Biolegend #128017), PE-conjugated anti-F4/80 (BM8.1, Biolegend
#123109), and FITC-conjugated anti-CD38 (90, Biolegend #102705), and then
ﬁxed and permeabilized with BD Cytoﬁx/Cytoperm kits (BD Biosciences
#BDB554714). After washing, the cells were stained with APC-conjugated antiNOS2 antibody (CXNFT, eBioscience #17-5920-80). The stained cells were analyzed using CytoFLEX ﬂow cytometer (Beckman Coulter), using CytExpert software version 2.3 and Flowjo software version 10.5.3 (BD).
Immunization of mice. Immunization of mice was performed as described
previously98. Brieﬂy, ovalbumin (200 μg/ml; OVA, Sigma-Aldrich #A5503) dissolved in PBS was emulsiﬁed in equal volume of Freund’s incomplete adjuvant
(IFA, Chemicon #AR002), or IFA containing either 10 mg/ml of Mtb H37Ra (CFA)
or MA, or both. Mice were intradermally injected at the tail base with 100 μl of
these emulsions. Twenty-eight days after immunization, spleen cells were collected
and stimulated ex vivo with 50 μg/ml of OVA for 3 days in RPMI-10 (1.0 × 106
cells/ml). The concentration of IFN-γ and IL-17A in the culture supernatants were
measured by ELISA (Biolegend #430801 and R&D systems #DY5390, respectively).
Phagocytic assay. M. bovis BCG (Tokyo 172 strain, Japan BCG laboratory
#876391) was labeled with FITC (SIGMA #F7250), as described previously99.
Brieﬂy, 6.0 × 107 CFU of M. bovis BCG were resolved in 200 μl of 0.1 M
carbonate–bicarbonate buffer (pH 9.6)/0.05% Tween 80 containing of 30 μg/ml
FITC, and incubated at 37 °C for 15 min. The FITC-labeled mycobacteria were
washed with PBS/0.05% Tween 80. For phagocytosis assay, WT or Trem2−/−
BMDMs (1 × 105) were incubated with 1 × 106 (MOI 10:1) of FITC-labeled
mycobacteria in a 96-well plate for 4 h at 37 °C. Negative controls were prepared in
identical conditions but incubated on ice (0 °C). The phagocytosis was stopped by
washing with ice-cold PBS. The phagocytosed mycobacteria were analyzed by ﬂow
cytometer after addition of 0.02% Trypan Blue to quench FITC ﬂuorescence of
extracellular but not internalized mycobacteria100.
M. bovis BCG infection. In vitro infection of M. bovis BCG was performed as
described previously101. Brieﬂy, BMDMs (1 × 105) were incubated in a 96-well
plate with 1 × 106 (MOI 10:1) of live M. bovis BCG for 4 h at 37 °C. After the
infection, uninfected bacteria were washed-out with RPMI-10 and the infected cells
were further cultured for 24 h in RPMI-10. The supernatant was collected and he
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nitrite concentration was measured by Griess assay. For CFU determination, the
cells were disrupted by water and plated on Middlebrook 7H10 agar (Difco
#262710) and number of BCG colonies was counted after 3-week culture.
Lung M. bovis BCG infection was performed as described previously102. Brieﬂy,
mice were intratracheally inoculated with 7.5 × 106 CFU of M. bovis BCG. The lung
tissues were collected at days 3 and 14 after infection, and homogenized by
gentleMACS. The homogenates were serially diluted in water and plated on
Middlebrook 7H10 agars and colonies were counted, as described above. Total
RNA was extracted from the lung homogenates and gene expression was analyzed
by qRT-PCR, as described above.
For T-cell recall response to mycobacterial antigens, mediastinal lymph node
cells were collected at day 14 after intratracheal infection and stimulated with 5 μg/
ml of tuberculin PPD (Japan BCG laboratory #114015) for 3 days. Concentration
of IFN-γ and IL-17 in the culture were measured by ELISA
Intraperitoneal M. bovis BCG infection was performed, as described
previously103. Brieﬂy, WT and Trem2−/− mice were infected intraperitoneally with
5 × 106 CFU of M. bovis BCG. The peritoneal lavages were collected at 4 h, day 1,
and day 3 after infection by washing the peritoneal cavity with 1 ml of RPMI-10.
The concentration of cytokines in the lavage was analyzed by ELISA. The
peritoneal cells were analyzed by ﬂow cytometry. CFU was counted as
described above.
Statistical analysis. All statistical analyses were carried out using GraphPad Prism
5 software. Two-tailed unpaired t test was performed for the comparisons between
two groups. One-way ANOVA or two-way ANOVA with Bonferroni post hoc test
were performed for the comparison of multiple groups. P values <0.05 were considered statistically signiﬁcant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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